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Objective: To evaluate the non-inferiority of pramipexole extended-release (ER) versus immediate-release (IR) in
Chinese patients with Parkinson’s disease (PD) in a double-blind, randomized, parallel-group study.
Methods: Subjects were Chinese patients with idiopathic PD with diagnosis≥ 2 years prior to trial, age≥ 30 years old
at diagnosis, and Modified Hoehn and Yahr score 2-4 during ‘on’-time. Subjects received treatment with pramipexole
ER (n=234) or IR (n=239). Non-inferiority was based on the primary endpoint, the change from baseline to end of
maintenance (week 18) in the UPDRS (Parts II + III) total score.
Results: For the primary endpoint, the adjusted mean changes (standard error) of UPDRS Parts II + III at week 18
were −13.81 (0.655) and −13.05 (0.643) for ER and IR formulations, respectively, using ANCOVA adjusted for treatment
and centre (fixed effect) and baseline (covariate). The adjusted mean between group difference was 0.8 for the 2-sided
95% CI (−1.047, 2.566). Since the lower limit of the 2-sided 95% CI (−1.047) for treatment difference was higher than the
non-inferiority margin of −4, non-inferiority between pramipexole ER and IR was demonstrated. The incidence of
adverse events (AEs) was 68.8% in the ER arm and 73.6% in the IR arm with few severe AEs (ER: 2.1%; IR: 3.8%).
Conclusion: Based on the UPDRS II + III score, pramipexole ER was non-inferior to pramipexole IR. The safety
profiles of pramipexole ER and IR were similar. These results were based on comparable mean daily doses and
durations of treatment for both formulations.
Keywords: Parkinson’s disease, Pramipexole ER, Pramipexole IR, Non-inferiority, Unified Parkinson’s Disease
Rating Scale (UPDRS), SafetyIntroduction
Parkinson’s disease (PD), a chronic degenerative neuro-
logical disorder involving motor and non-motor dysfunc-
tions, inflicts emotional, financial and social burdens on
patients, their families, and their social network [1]. The
prevalence in the United States is 1-2% in persons at least
65 years of age and 4-5% in persons over 85 years. The
prevalence in China in those aged 65 years or older is
similar (1.7%) [2].* Correspondence: chen_sd@medmail.com.cn
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unless otherwise stated.Dopamine substitution with either L-dopa or dopa-
mine agonists (DAs) remains the main therapy for PD
patients [3]. However, prolonged treatment with L-dopa
could lead to frequent, disabling motor complications
[4]. To delay the occurrence of L-dopa-related motor
complications, patients with early PD often receive
DAs as monotherapy, while most advanced PD patients
receive L-dopa with a DA to reduce existing motor
complications. Pramipexole (immediate-release [IR] and
extended-release [ER]) is a non-ergot DA with a high
selectivity for the D2 subfamily of dopamine receptors,
with preferential affinity for D3 receptors, contributing to
its excellent efficacy and acceptable side effect profiletd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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demonstrated in two international, placebo-controlled,
double-blind, pivotal studies in patients with early PD
(Asians 36.5%) and advanced PD (Asians 49.7%) after
18 weeks of treatment, with the Unified Parkinson’s
Disease Rating Scale (UPDRS) II and III total score as
primary endpoint [8,9] and in a 12-week study in Japanese
patients with PD [10].
An evaluation of pramipexole ER versus IR in Chinese
patients with PD has not previously been undertaken.
This study tested for non-inferiority of pramipexole ER
versus IR in Chinese patients with PD who could be
concomitantly treated with L-dopa.
Patients and methods
Patients
The study enrolled early and advanced PD patients from
20 centers across China (September 2010 - January 2012).
Subjects were Chinese patients diagnosed with idiopathic
PD for at least 2 years; age ≥ 30 years old at diagnosis,
Modified Hoehn and Yahr (H&Y) score of 2 to 4 during
‘on’-time. In patients taking standard or controlled release
L-dopa or L-dopa/entacapone, dose has to be optimized
and stable for at least 4 weeks prior to the baseline visit.
If patients had motor fluctuations while taking L-dopa,
‘off ’-time at waking should be no more than 6 hours
daily during 2 consecutive days before the baseline visit.
All procedures were performed with the understand-
ing and written consent of the subjects and with the
approval of institutional review boards at participating
institutions (Appendix).
Randomization and study intervention
Randomization was conducted by a validated system
using a pseudo-random number generator, making
treatment assignment reproducible but not predictable.
Patients underwent randomization in blocks of four at a
1:1 ratio to receive oral pramipexole ER or IR tablets.
Randomization was stratified by center. Throughout the
study, the persons who administered the medications,
the raters, and the patients were all blind to medication
assignments.
The 18-week treatment course consisted of two phases:
up-titration (<7 weeks) to achieve optimal treatment
response and maintenance (11 weeks), followed by down-
titration. Pramipexole ER doses ranging from 0.375 mg to
4.5 mg per day were identical to approved daily doses for
IR. All patients received routine care. The trial permitted
treatment with common anti-PD medications if ad-
ministered at a stable dose for at least 4-weeks prior to
enrollment and if no dose change was planned during
the treatment phase. The trial prohibited use of DA or
central dopaminergic antagonist within 4-weeks prior
to enrollment.Clinical assessment
Investigators determined the Modified H&Y scale stages
(0–5). PD symptoms were assessed by the UPDRS Part
II (Activities of Daily Living (ADLs)) and III (Motor
Examination) for both ‘off ’ and ‘on’ periods [11,12]. A
treatment response was a decrease of score by at least
20% from baseline. UPDRS II score was calculated as
mean of the ‘off ’-time and ‘on’-time for advanced PD
patients and as on-time for early PD patients. UPDRS III
score was only assessed for the ‘on’-time. The Mini-
Mental State Examination (MMSE) was used [13]. Sub-
jects self-evaluated the likelihood of dozing with Epworth
Sleepiness Scale [14]. General status was evaluated by the
Clinical Global Impressions of Improvement (CGI-I) scale
and overall status by the Patient Global Impression of
Improvement (PGI-I) scale (1 point: very much better; 7
points: very much worse in both scales). The response
based on CGI or PGI-I was defined as a rating of at least
‘much better’ when comparing the past week to baseline
assessment.
Safety assessment
Vital signs and adverse events were monitored through-
out the study. Safety assessments were based mainly on
the occurrence, frequency, and severity of adverse events
(AEs), but also included comprehensive indexes (e.g.
physical examination, electrocardiography, ophthalmo-
logic monitoring, and routine laboratories). Safety data
were collected from baseline through end of down-
titration. AEs were considered mild if they were easily
tolerated, moderate if they interfered with usual activity,
and severe if they were incapacitating or caused inability to
work or to perform usual activities. AEs were considered
serious if they resulted in death, were immediately life-
threatening, resulted in persistent or significant disability/
incapacity, required or prolonged patient hospitalization,
were a congenital anomaly/birth defect, or were deemed
serious for any other reason.
Statistical analysis
Sample size calculations determined that 223 subjects
were required in each pramipexole group to have 90%
power, assuming a non-inferiority margin between ER
and IR of −4 points, a standard deviation (SD) of 13, and
testing with a one-sided 97.5% confidence interval (CI).
Results were presented as 95% 2-sided confidence inter-
val, to allow the calculation of the two sides of the CI.
One-sided 97.5% CI & two-sided 95% CI will yield the
same results and are equivalent. To allow for early drop-
outs, the estimated target sample size was 234 subjects
per group. The sample allocation was 1:1.
The statistical analyses were pre-specified. The full
analysis set (FAS) included all patients who were
randomized to treatment, received at least one dose of
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assessment and at least one post-baseline assessment for
primary endpoint. The treated set (TS) included all pa-
tients who were dispensed study medication and were
documented to have taken at least one dose. The per-
protocol set (PPS) included all evaluable patients from the
FAS who completed at least 14 weeks ± 3 days of active
treatment and presented no major protocol violation.
Unless otherwise specified, all efficacy results were
based on FAS, whereas for patients who withdrew or
were lost to follow-up, the last observation carried
forward approach (LOCF) was used. For all analyses,
data were censored on the date of first intake of L-dopa as
rescue medication for patients who had not been taking
concomitant L-dopa at baseline. If used (e.g. for FAS
analysis), the LOCF approach was applied after censoring.
The primary efficacy endpoint was the change from
baseline to the end of the maintenance at week 18 in
UPDRS II + III scores (0–160 points). Non-inferiority
was based on comparison of lower bound of 2-sided
95% CI using a non-inferiority margin of −4 points and
evaluated with an analysis of covariance (ANCOVA)
adjusted for treatment and centre (fixed effects) and
baseline (covariate).
Statistical analyses on secondary endpoints were
designed to show superiority of pramipexole ER vs. IR.
Secondary continuous parameters were analysed using
an ANCOVA model with same effects as primary end-
point, but using the respective baseline values of the
following continuous endpoints as covariate: the per-
centage and duration of ‘off ’-time during waking hours
(diary based, patients with advanced PD); the percent-
age and duration of ‘on’-time during waking hours,
without dyskinesia or with non-troublesome dyskin-
esia, or with troublesome dyskinesia; and the UPDRS
Part II and Part III scores calculated separately.
The Cochran-Mantel-Haenszel test adjusted for centre
was applied to these binary parameters:
 The proportion of patients with at least a 20%
improvement relative to baseline in the percentage
‘off ’-time during waking hours (diary based, advanced
patients),
 The responder rate (at least much better/improved)
for CGI-I and PGI-I,
 The proportion of patients with at least a 20%
improvement relative to baseline in the UPDRS II + III
score, and,
 The proportion of patients requiring L-dopa supple-
mentation during the study (for patients without
concomitant L-dopa at baseline).
Descriptive statistics based on the TS were used to analyze
safety data, demographic and baseline characteristics,concomitant diseases and medication, and treatment
compliance. AE analyses were based on number of
patients with AEs (not number of AEs) and presented
as descriptive statistics. SAS 9.2 software package was
used for all statistical analyses.
Results
Demographic, baseline and treatment characteristics of
the study participants
As depicted on subject flowchart (Additional file 1:
Figure S1), 524 patients were eligible. Finally, 475
patients were randomized to receive pramipexole ER
(n = 236) or IR (n = 239) and 473 patients received the
assigned treatment of ER (n = 234) or IR (n = 239).
Demographics and baseline conditions were compar-
able between the two arms (Table 1). The mean age
(SD) of the subjects was 62 (9.06) years and 39.5% of
them were at least 65 years old. The study population
comprised 63% male. Slightly more patients had early
PD (53.9%) than advanced PD (46.1%). The mean (SD)
UPDRS II + III score was 44.9 (16.51) with a majority
of the patients in H&Y stage 2 to 3 for on-phase. The
high missing rate of the H&Y stage for the ‘off ’ phase
for subjects taking ER (44.0%) and IR (42.7%) was
largely related to those subjects with early PD in whom
an ‘off ’ phase H&Y stage was not recorded. The mean
duration of PD (SD) was 4.96 (3.21) years.
Previous and concomitant medications (Additional file 2:
Figure S2) were generally balanced between treatment
arms. Previous PD therapies were reported in 11.6% of
patients, with most being L-dopa and its derivatives
(6.1% of patients) and DAs (5.3% of patients). Con-
comitant anti-PD therapies were reported in 94.7% of
patients. At baseline, 86% of patients were receiving
L-dopa or its derivatives, with mean dose of 433.1 ±
204.9 mg. There were few patients (ER 5.1%, IR 7.9%)
with add-on therapies for PD.
At final assessment, most patients (ER 72.6%; IR
69.9%) were receiving a low daily dose (0.375, 0.75, or
1.5 mg) of study drug (mean, ER: 1.5 mg; IR: 1.6 mg).
The mean treatment compliance was very high in both
treatment arms (ER 99.0%, IR 100.1%).
Primary outcome
The patients without UPDRS II + III score at baseline or
during treatment were excluded, 228 patients in ER arm
and 236 patients in IR arm were included in efficacy
analysis. Both arms showed a similar improvement with
most of improvement in UPDRS II + III scores after
6 weeks of treatment (Figure 1A). The mean (standard
error) UPDRS II + III score at week 18 was 31.13 (0.97)
for ER and 32.15 (1.04) for IR. For the primary endpoint,
the adjusted mean changes (SE) of UPDRS Parts II + III
at week 18 compared to baseline were −13.81 (0.655)
Table 1 Demographic and clinical characteristics of the study participants at baseline
Characteristic Pramipexole ER Pramipexole IR Total
n=236 n=239 n=475
Age, mean (±SD) years 62.2(9.10) 61.8(9.03) 62.0(9.06)
<65 140(59.8) 146(61.1) 286(60.5)
≥65 94(40.2) 93(38.9) 187(39.5)
Female sex, n (%) 80(34.2) 95(39.7) 175(37.0)
Body mass index, mean (±SD) kg/m2 23.3(2.85) 23.3(3.06) 23.3(2.95)
Hoehn and Yahr stage, n (%)
On phase
2-3 226(96.6) 234(97.9) 460(97.3)
4-5 8(3.4) 5(2.1) 13(2.7)
Off phase
2-3 113(48.3) 119(49.8) 232(49.0)
4-5 18(7.7) 18(7.5) 36(7.6)
Missing 103(44.0) 102(42.7) 205(43.3)
UPDRS score, mean (±SD)
II 13.0(4.92) 13.0(5.97) 13.0(5.47)
III 31.7(12.09) 32.1(12.78) 31.9(12.43)
II+III 44.7(15.69) 45.1(17.31) 44.9(16.51)
PD stage, n (%)
Early 122(52.1) 133(55.6) 255(53.9)
Advanced 112(47.9) 106(44.4) 218(46.1)
Duration of disease, mean (±SD) years 5.11(3.33) 4.82(3.09) 4.96(3.21)
2 to <5, n (%) 146(62.4) 153(64.0) 299(63.2)
≥5, n (%) 88(37.6) 86(36.0) 174(36.8)
MMSE score, mean (±SD) 28.4(1.61) 28.4(1.44) 28.4(1.52)
ESS score, mean (±SD) 5.0(3.81) 5.4(4.13) 5.2(3.97)
EES, Epworth sleepiness scale; MMSE, Mini Mental State Examination; PD, Parkinson’s disease; UPDRS, Unified Parkinson’s Disease Rating Scale.
The chi-square test was used for categorical variables, and one-way analysis of variance for continuous variables. There were no significant between-group differences
in any baseline characteristics.
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ively, using ANCOVA adjusted for treatment and centre
(fixed effect) and baseline (covariate). The adjusted mean
between group difference was 0.8 for the 2-sided 95% CI
(−1.047, 2.566). Since the lower limit of the 2-sided 95%
CI (−1.047) for treatment difference was higher than
the non-inferiority margin of −4, ER was shown to be
non-inferior to IR. There was no statistical difference
between the two arms at week 18 or at any other study
visits.
Responder patients for the UPDRS II + III score were
those with a decrease of the score by at least 20% from
baseline. The overall response rate for UPDRS II + III
score steadily increased from 24.4% at week 2 to 67.7%
at week 8 and thereafter stayed relatively constant
(Figure 1B). At week 18, the response rate was slightly
higher in ER arm (71.9%) than in IR arm (65.3%), but
without a statistically significant difference.Secondary outcomes
The mean (SE) ‘off ’-time percentage during waking hours
at baseline for advanced PD patients was 27.78 (0.81) for
ER and 30.80 (1.21) for IR, and decreased to 21.68 (1.53)
at week 18 for ER and 22.46 (1.61) for IR, respectively
(no statistical difference for superiority). The adjusted
mean change (ANCOVA) from baseline was −6.96 (1.51)
for ER and −7.4 (1.54) for IR. The adjusted mean change
(ANCOVA) from baseline in the mean duration of ‘off ’-
time was comparable between the two arms (ER: −1.0
(0.23) h; IR: −1.1 (0.23) h). Furthermore, the two arms re-
vealed a similar response with most of the improvement
having occurred after approximately 6 weeks of treatment
(Figure 2). No difference was observed in the mean ‘off ’-
time percentage or duration between the two arms at any
study visit (ANCOVA). Additionally, a similar response
rate for ‘off ’-time was observed in the ER and IR arms
after 18 weeks (52.7% vs. 55.7%).
Figure 1 Improvement in UPDRS II + III scores in both arms. (A) Adjusted mean change (±SE) in UPDRS II + III score over time, full analysis
set (FAS) (last observation carried forward, LOCF). Since the lower limit of the 2-sided confidence interval for treatment difference was higher than the
non-inferiority margin, pramipexole ER was non-inferior to pramipexole IR. (B) Percentage of UPDRS II + III responder patients over time, FAS (LOCF). At
week 18, the response rate was slightly higher in the ER arm than in the IR arm, but without a statistically significant difference between the arms.
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without dyskinesia comprised the majority of waking
hours (ER: 67.98%; IR: 65.09%). The adjusted mean
percentage/duration of on-time without dyskinesia in-
creased in both groups: +7.0%/1.0 h (ER) and +4.3%/
0.5 h (IR) (ANCOVA). The adjusted mean change
(ANCOVA) from baseline in mean percentage of on-
time without dyskinesia or with non-troublesome dys-
kinesia was 6.86 (1.57) for ER and 7.48 (1.60) for IR. The
adjusted mean change (ANCOVA) from baseline in the
mean duration of ‘on’-time without dyskinesia or with
non-troublesome dyskinesia was +1.0 (0.26) h in both
arms with no significant difference between the two
arms at all study visits (ANCOVA) (Additional file 3:
Figure S3). ‘On’-time with troublesome dyskinesia repre-
sented about 1% of waking hours reported by advancedPD patients, and only insignificant changes occurred
during the treatment period in both arms.
The overall response rate for CGI-I increased from
41.2% at week 4 to 59.3% at week 8 and thereafter stayed
relatively stable (Additional file 4: Figure S4A). At week
18, there were similar response rates for ER and IR
(55.8% vs. 59.2%, no statistical difference). The overall
response rate for PGI-I steadily increased from 12.1% at
telephone call to 50.6% at week 6 and thereafter stayed
relatively stable (Additional file 4: Figure S4B). At week
18, there were similar response rates for ER and IR
(52.2% vs. 53.8%, no statistical difference).
In patients without concomitant L-dopa treatment at
baseline, only 1 patient (ER arm) required L-dopa sup-
plementation during study. As there was only one obser-
vation, the CMH test was not performed.
Figure 2 Reduction of ‘off’-time in advanced PD patients. (A) Adjusted mean change in the percentage of ‘off’-time over time in patients
with advanced Parkinson disease (PD), full analysis set (FAS) (last observation carried forward, LOCF); (B) Adjusted mean duration (±SE) of ‘off’-time. For
A and B: No difference was observed in the adjusted mean percentage ‘off’-time or duration between the two arms at any study visit (ANCOVA).
Wang et al. Translational Neurodegeneration 2014, 3:11 Page 6 of 9
http://www.translationalneurodegeneration.com/content/3/1/11Safety
The incidence of AEs was lower for ER (68.8%) than for
IR (73.6%) (Table 2). The three most common AEs were
somnolence (ER: 21.8%; IR: 14.6%), dizziness (ER: 12.8%;
IR: 13.0%), and nausea (ER: 8.5%; IR: 7.1%). There were
few severe AEs (ER: 2.1%; IR: 3.8%). The incidence of
serious AEs was 2.6% for ER and 5.4% for IR. Incidences
of drug-related AEs were similar (ER: 50.0%; IR: 52.7%).
The three most common drug-related AEs were somno-
lence (ER: 18.8%; IR: 14.6%), dizziness (ER: 11.5%; IR:
12.1%), and nausea (ER: 7.3%; IR: 6.3%). Few AEs led to
treatment discontinuation (ER: 4.7%; IR: 5.0%). A lower
AE rate was observed in advanced PD patients treated
with ER (67.9%) than those treated with IR (77.4%),
while the rate was balanced for patients with early PD.
AE System Organ Classes with an incidence rate of 10%
or higher in either treatment arm were nervous system
disorders (ER: 41.0%; IR: 36.8%), gastrointestinal disor-
ders (ER: 25.6%; IR: 24.3%), and eye disorders (ER:
11.1%; IR: 13.0%). Of the treatment emergent AEs ofeye disorders, blurred vision (ER: 3.4%, IR: 1.7%) and
cataracts (ER: 2.1%, IR: 1.3%) occurred most frequently.
The incidence of orthostatic hypotension was low in both
arms (ER: 6.8%; IR: 5.1%), with about 1/3 of all cases being
symptomatic.
Discussion
Although prior studies demonstrated the non-inferiority
of pramipexole ER versus IR, as reflected by improve-
ment in UPDRS II and III scores after 18 weeks [8,9], no
study of ER versus IR had been undertaken in Chinese
patients with early and advanced PD. In this random-
ized, double-blind, double dummy, parallel-group study,
ADLs of PD patients were improved by pramipexole ER,
as evidenced by improvement in UPDRS Part II score
assessed in the ‘off ’ and ‘on’ periods, and mean of the
‘off ’/‘on’ periods. This study showed similar improve-
ments in motor function, as reflected by changes in
UPDRS Part III score. ER improved UPDRS II + III total
scores at week 18 with most of the improvement having
Table 2 Treatment emergent adverse effects in the study participants
Characteristic Pramipexole ER Pramipexole IR Total
n=234 n=239 n=473
Patients with any AE 161(68.8) 176(73.6) 337(71.2)
Severe AEs 5(2.1) 9(3.8) 14(3.0)
Drug-related AEs 117(50) 126(52.7) 243(51.4)
AEs leading to discontinuation 11(4.7) 12(5.0) 23(4.9)
Serious AEs 6(2.6) 13(5.4) 19(4.0)
Nervous system disorders 96(41.0) 88(36.8) 184(38.9)
Somnolence 51(21.8) 35(14.6) 86(18.2)
Dizziness 30(12.8) 31(13.0) 61(12.9)
Dyskinesia 12(5.1) 18(7.5) 30(6.3)
Tremor 4(1.7) 6(2.5) 10(2.1)
PD 3(1.3) 9(3.8) 12(2.5)
Gastrointestinal disorders 60(25.6) 58(24.3) 108(22.8)
Nausea 20(8.5) 17(7.1) 37(7.8)
Constipation 17(7.3) 20(8.4) 37(7.8)
Abdominal discomfort 3(1.3) 7(2.9) 10(2.1)
Upper abdominal pain 6(2.6) 6(2.5) 12(2.5)
Vomiting 5(2.1) 5(2.1) 10(2.1)
Eye disorders 11(4.7) 8(3.3) 19(4.0)
Vascular disorders 8(3.4) 11(4.6) 19(4.0)
Orthostatic hypotension 5(2.1) 4(1.7) 9(1.9)
Hypotension 1(0.4) 5(2.1) 6(1.3)
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inferiority indicated that ER was non-inferior to IR in
improving ADLs and motor function of PD patients.
Both arms showed similar overall response rates assessed
by UPDRS II + III score. Analyses of secondary end-
points confirmed the findings for primary endpoint,
showing similar results for both treatments. Exploratory
comparisons revealed no difference between the two
treatments for secondary endpoints, with the exception
of the change in on-time with non-troublesome dyskin-
esia during waking hours, where the results favored IR.
Pramipexole ER and IR similarly reduced the ‘off ’
period and increased the ‘on’ period without dyskinesia
or with non-troublesome dyskinesia. Similar response
rates for CGI-I and PGI-I were observed for ER and IR.
These findings established the efficacy of pramipexole
ER and its non-inferiority to IR. These findings are con-
sistent with the results of the pivotal studies in patients
with early and advanced PD [8,9].
An earlier study of pramipexole in Chinese patients
with early or advanced PD in Hong Kong and Taiwan
showed that pramipexole is safe and well-tolerated [15].
We found similar safety profiles of ER and IR tablets
with no unexpected safety risks. This finding is consistentwith an early study [16] showing no significant difference
in AE profiles between the two pramipexole formulations.
The three most common drug-related AEs in our study
were somnolence, dizziness, and nausea. These may not
be drug-specific as a similar rate of AEs has been reported
for pramipexole ER and the placebo [10]. As in earlier
studies [17], hypotension was seen in a very small propor-
tion of our patients.
In conclusion, pramipexole ER is non-inferior to pra-
mipexole IR based on the UPDRS II + III score at week
18. Both formulations are safe and well-tolerated by the
patients and are effective for early and advanced PD in
Chinese patients. These results are based on comparable
mean daily doses and durations of treatment for both
formulations.
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